Insider Spends US$67k Buying More Shares In AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript

AngioDynamics Third Quarter 2024 Earnings: Misses Expectations

Buy Rating Affirmed for AngioDynamics Amid Strong Sales and Strategic Growth Opportunities

AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates

AngioDynamics' (ANGO) AlphaVac Gets FDA Nod for PE Treatment

Buy Rating Reaffirmed for AngioDynamics Amidst Strategic Growth and Med-Tech Sector Potential

Q3 2024 AngioDynamics Inc Earnings Call

Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars

AngioDynamics Inc (ANGO) Posts Q3 Fiscal 2024 Results: A Mixed Performance Amidst Asset Divestiture

Options Volatility and Implied Earnings Moves Today, April 04, 2024

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE

AngioDynamics (ANGO) Settles Patent Litigations With BD

AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.

Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for

Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for

AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024

AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors

AngioDynamics (ANGO) Declines More Than Market: Some Information for Investors